EXPLORING TEMPERATURE CONTROLLED REQUIREMENTS AND LIMITATIONS FOR WEIGHT LOSS MEDICATIONS (GLP-1)
In the last decade, obesity and its associated health issues have become increasingly prevalent worldwide (1,2). While various weight loss methods exist, ranging from the traditional “eat healthy and exercise” to the more extreme option of bariatric surgery, many individuals are now turning to weight-loss drugs, originally marketed towards type 2 diabetics; more specifically, the GLP-1 receptor agonist drugs. Glucagon-Like Peptide 1 (GLP-1) is a naturally occurring hormone in the body that plays a critical role in regulating blood sugar levels. Injectable drugs, such as semaglutide, liraglutide, and diraglutide, involve GLP-1 receptor agonists, which simulate the actions of natural GLP-1 by binding to and stimulating its receptors.
This boost in GLP-1 activity can lead to weight loss through several mechanisms: slowing the rate at which your stomach empties to reduce hunger and minimize the amount of glucose spikes, decreasing glucagon formation and the resultant glucose in the bloodstream, and stimulating insulin release from the pancreas when blood sugar levels are high, such as after meals (3, 4, 5). Originally designed to help individuals with type 2 diabetes, some GLP-1 receptor agonist drugs have been specifically formulated for weight loss. A substantial body of research supports their safety and effectiveness in this role (6). As these types of drugs become safer and more effective, their usage is expected to grow significantly. A poll conducted in May 2024 revealed that 1 in 8 adults in the U.S. had used a GLP-1 injectable (7).
SHIPPING AND SAFETY
Proper temperature and lighting control throughout the shipping process is crucial to maintaining safety and adhering to standards, and in so doing, safeguarding patient health. If medications are exposed to excessive heat, cold, or light, their efficacy can be compromised, particularly those that are not in solid forms like capsules or tablets, such as injectables. These extreme temperature and lighting conditions can cause chemical changes in the active ingredients, potentially leading to reduced effectiveness or, concerningly, adverse reactions (12, 13). Moreover, it is imperative to focus on minimizing costs and reducing waste generated from these shipments.
Different weight loss and diabetes drugs such as Ozempic and Wegovy have varying storage requirements. While some require refrigeration at temperatures between 2 and 8 degrees celsius, others can be stored at room temperature (between 2 and 30 degrees celsius) for a certain period of time. TempAid offers temperature-controlled PCM mailers that cater to both refrigerated and room temperature shipments, depending on the drug’s requirements. These mailers are single use, end-user developed envelopes, which are ideal for residential deliveries of GLP-1 single use injectables. Users typically require regular shipments as they are prescribed a 1-month supply at a time, with the potential to stay on the drug indefinitely (9,10) for semaglutide; Ozempic and Wegovy). Since the shipments are small, containing only a box with a pen or pens, the SpeedyPac mailers are perfectly suited for the task of shipping home self injectables. This design eliminates the need for extensive packing materials that are required for larger shipments, such as large corrugated boxes and EPS coolers. (Although SpeedyPacs are better suited for home self injectables, large corrugated boxes and EPS coolers remain ideal for shipping large quantities to pharmacies or other businesses for commercial purposes).
HOW TO SHIP GLP-1’S
The SpeedyPac mailers significantly reduce shipping waste, which is particularly beneficial given the frequency of shipments for these single use injectables. Additionally, the compact design of these mailers minimizes space and material usage, leading to reduced overall shipping costs. While ensuring proper temperature requirements and safety of the shipment is paramount, the convenience offered to patients is also significant.
Having these single-use injectables shipped directly to patient homes saves travel and time that would otherwise be spent picking them up at a pharmacy. This approach is not only more convenient, but it also significantly improves accessibility for patients with mobility issues. More importantly, regular home deliveries can help prevent missed doses by eliminating the need to remember to order or pick up the medication.
CONCLUSION
As weight loss and diabetes management medications continue to experience rapid growth, the need for proper storage conditions during transportation will become increasingly critical. The efficacy of drugs like Wegovy and Ozempic depends not only on their formulation, but also on maintaining their integrity throughout the shipping process. Temperature-controlled packaging plays a crucial role in maintaining the stability and effectiveness of GLP-1 single-use injectables by ensuring they are kept within optimal conditions during transit. By addressing both the need for precise temperature control and the desire to reduce environmental impact, SpeedyPac’s offer a forward-thinking approach to pharmaceutical shipping processes. The use of these innovative, compact PCM mailers not only enhances medication safety and stability during delivery, but also reduces the time and complexity of shipping logistics on the distributors. They also significantly improve patient convenience and adherence by ensuring timely and consistent delivery standards. As the market for these types of medications grows, investing in such advanced cold-chain packaging solutions like SpeedyPac’s will be vital to supporting patient health and optimizing the delivery process.
Have questions about weight loss medication shipping and storage? Reach out to TempAid.
References
1. Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023, January 2). GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers.
2. Malik VS, Willet WC, Hu FB. Nearly a decade on, trends, risk factors and policy implications in global obesity. Nat Rev Endocrinol (2020) 16:615–6. doi: 10.1038/s41574-020-00411-y
3. Mayo Foundation for Medical Education and Research. (2022, June 29). Do any diabetes drugs help you lose weight?. Mayo Clinic.
4. Cleveland Clinic Health Library. (2023, July 3). GLP-1 agonists. Cleveland Clinic.
5. Collins, L. (2024, February 29). Glucagon-like peptide-1 receptor agonists. National Institute of Health: National Center for Biotechnology Information.
6. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet (2021) 398:262–76. doi: 10.1016/S0140-6736(21)00536-5
7. Montero, A., Sparks, G., Presiado, M., & Hamel, L. (2024, May 10). KFF Health Tracking Poll May 2024: The public’s use and views of GLP-1 Drugs. KFF.
8. Morgan, J. P. (2023, November 29). The increase in appetite for obesity drugs. J.P. Morgan Global Research.
9. Kindelan, K. (2024, May 20). New study focuses on what happens if you stay on weight loss drug Wegovy for years. ABC News.
10. Fick, M. (2024, May 14). Wegovy users keep weight off for four years, Novo Nordisk study says. Reuters.
11. Ozempic this, Wegovy that: No matter what you call it, Semaglutide is having a moment. DrFirst. (2023, October 17).
12. Highland Pharmacem. (2024, May 30). The significance of temperature in medications storage. Highland (Shandong) Pharmaceutical Technology Co.Ltd.
13. Sumners, C. (2018, October 11). Drug stability: How storage conditions affect their performance. Vital Record. Texas A&M University Health.
